<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533273</url>
  </required_header>
  <id_info>
    <org_study_id>AUX CC 859</org_study_id>
    <nct_id>NCT00533273</nct_id>
  </id_info>
  <brief_title>Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease</brief_title>
  <acronym>CORD-II</acronym>
  <official_title>A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Followed by an Open-Label Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 12-month study had two phases: a 90-day double-blind, randomized, placebo-controlled
      phase and a nine-month open-label extension phase. Before treatment, eligible subjects were
      stratified by the primary joint type (30 metacarpophalangeal [MP] joints and 30 proximal
      interphalangeal [PIP] joints) and by severity of the primary joint contracture (ie, up to 50°
      or &gt;50° for MP joints and up to 40° or &gt;40° for PIP joints) and then randomized in a 2:1
      ratio to either AA4500 0.58 mg or placebo. Upon completion of the double-blind phase (ie,
      90-day evaluation after the first injection), all subjects were eligible to enter the
      open-label extension phase of the study in which they were followed for an additional nine
      months. Subjects who required further treatment because they either did not achieve reduction
      in contracture to 5° or less, the cord affecting the primary joint received placebo, another
      cord received less than three injections of AA4500, or they had untreated cords that were
      affecting other joints had the option to receive up to five additional injections of AA4500
      0.58 mg in the open-label extension phase, with individual cords receiving up to three
      injections of AA4500.

      This study was designed to be part of the larger clinical program, for adult patients with
      Dupuytren's contracture with a palpable cord, where the data from 2 pivotal
      Placebo-Controlled studies (AUX-CC-857 [NCT00528606] and AUX-CC-859 [NCT00533273]) and 7
      non-pivotal studies were evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Primary Joint Contracture to 5° or Less</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Within 30 days after last injection</time_frame>
    <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion in Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion − baseline range of motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Clinical Success in Primary Joint</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success in Primary Joint After the First Injection</measure>
    <time_frame>Within 30 days after first injection</time_frame>
    <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Within 30 days after first injection</time_frame>
    <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture of Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion in Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in Non-Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Within 30 days after last injection</time_frame>
    <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion − baseline range of motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Clinical Success in Non-Primary Joint</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success in Non-Primary Joint After the First Injection</measure>
    <time_frame>Within 30 days after first injection</time_frame>
    <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in Non-Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Within 30 days after first injection</time_frame>
    <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion in Non-Primary Joint After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Advanced Dupuytren's Disease</condition>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collagenase clostridium histolyticum</intervention_name>
    <description>Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.</description>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>XIAFLEX®</other_name>
    <other_name>AA4500</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion
             deformity of at least one finger, other than the thumb, that had a contracture at
             least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a
             palpable cord.

          -  Had a positive &quot;table top test,&quot; defined as the inability to simultaneously place the
             affected finger(s) and palm flat against a table top.

          -  Were naive to AA4500 treatment

          -  Were judged to be in good health, based upon the results of a medical history,
             physical examination, and safety laboratory profile.

        Exclusion Criteria:

          -  Had a chronic muscular, neurological, or neuromuscular disorder that affected the
             hands.

          -  Had received a treatment for advanced Dupuytren's disease, including surgery
             (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of
             verapamil and/or interferon on the selected primary joint within 90 days before the
             first dose of study drug.

          -  Had a known recent history of stroke, bleeding, a disease process that affected the
             hands, or other medical condition, which in the investigator's opinion, would make the
             subject unsuitable for enrollment in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Urdaneta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rivercity Research</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brisbane Hand &amp; Upper Limb Clinic</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caboolture Clinical Research Centre</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Clinical Research Centre</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <zip>4019</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menzies Reserarch Institute</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Shenton Park</city>
        <state>Western Australia</state>
        <zip>6007</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf</url>
    <description>XIAFLEX Medication Guide</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf</url>
    <description>XIAFLEX Prescribing Information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <results_first_submitted>September 24, 2010</results_first_submitted>
  <results_first_submitted_qc>September 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2010</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AA4500 0.58 mg</title>
          <description>Collagenase clostridium histolyticum 0.58 mg injected into metacarpophalangeal (MP) and/or proximal interphalangeal (PIP) joints</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (Sucrose and Tris) injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64">open-label was extension of double-blind; 64 of 66 patients continued into open-label</participants>
                <participants group_id="P2" count="0">no placebo - this phase was open label</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AA4500 0.58 mg</title>
          <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (Sucrose and Tris) injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="7.8"/>
                    <measurement group_id="B2" value="65.5" spread="11.1"/>
                    <measurement group_id="B3" value="63.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Primary Joint Contracture to 5° or Less</title>
        <description>Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Primary Joint Contracture to 5° or Less</title>
          <description>Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in Primary Joint After the Last Injection</title>
        <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, Within 30 days after last injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in Primary Joint After the Last Injection</title>
          <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection</title>
        <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection</title>
          <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="29.21"/>
                    <measurement group_id="O2" value="13.6" spread="26.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion in Primary Joint After the Last Injection</title>
        <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion in Primary Joint After the Last Injection</title>
          <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion − baseline range of motion</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="17.77"/>
                    <measurement group_id="O2" value="7.6" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Clinical Success in Primary Joint</title>
        <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Clinical Success in Primary Joint</title>
          <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not reach Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success in Primary Joint After the First Injection</title>
        <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after first injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success in Primary Joint After the First Injection</title>
          <description>Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.014</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in Primary Joint After the First Injection</title>
        <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, Within 30 days after first injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in Primary Joint After the First Injection</title>
          <description>Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture of Primary Joint After the First Injection</title>
        <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture of Primary Joint After the First Injection</title>
          <description>Percent change in degree of contracture of primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="31.74"/>
                    <measurement group_id="O2" value="6.0" spread="20.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion in Primary Joint After the First Injection</title>
        <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Subjects who were randomized and received at least 1 injection</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (Sucrose and Tris) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion in Primary Joint After the First Injection</title>
          <description>Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
          <population>Subjects who were randomized and received at least 1 injection</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="17.41"/>
                    <measurement group_id="O2" value="3.6" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection</title>
        <description>Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection</title>
          <description>Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in Non-Primary Joint After the Last Injection</title>
        <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, Within 30 days after last injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in Non-Primary Joint After the Last Injection</title>
          <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection</title>
        <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection</title>
          <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="34.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection</title>
        <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection</title>
          <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion − baseline range of motion</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="16.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Clinical Success in Non-Primary Joint</title>
        <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Clinical Success in Non-Primary Joint</title>
          <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not reach Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success in Non-Primary Joint After the First Injection</title>
        <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after first injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success in Non-Primary Joint After the First Injection</title>
          <description>Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in Non-Primary Joint After the First Injection</title>
        <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, Within 30 days after first injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in Non-Primary Joint After the First Injection</title>
          <description>Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection</title>
        <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection</title>
          <description>Percent change in degree of contracture of non-primary joint measured as 100 * (baseline contracture − last available post-injection contracture prior to next injection)/baseline contracture</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="38.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion in Non-Primary Joint After the First Injection</title>
        <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion in Non-Primary Joint After the First Injection</title>
          <description>Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection − baseline range of motion</description>
          <population>Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs &amp; SAEs were collected until 30 days after completion or discharge from study.</time_frame>
      <desc>This study was designed to be part of the larger clinical program. For information regarding XIAFLEX-associated Serious and Non-serious Adverse events please refer to the XIAFLEX Medication Guide &amp; XIAFLEX Prescribing Information (see links above)</desc>
      <group_list>
        <group group_id="E1">
          <title>AA4500 0.58 mg</title>
          <description>collagenase clostridium histolyticum 0.58mg injected into metacarpophalangeal (MP) and/or proximal interphalangeal (PIP) joints</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo injection is comprised of sucrose and Tris</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Orbital cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="76" subjects_affected="27" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="61" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="55" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="163" subjects_affected="54" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site vesicles</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="136" subjects_affected="46" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="82" subjects_affected="36" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="26" subjects_affected="13" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

